Yu: Vevo generated Tahoe dataset with four people in three days
Johnny Yu · No Priors Ep. 103 | With Vevo Therapeutics and the Arc Institute · Feb 25, 2025 · at 31:20
Johnny Yu, CSO and co-founder of Vevo Therapeutics, describes the operational execution behind generating the Tahoe perturbation dataset.
0:00 / 0:06exact quote · 6.3s
▶ Watch the full episode on YouTube → 720p mp4 · rendered on demand · StarZero watermark
“Well, it ended up being actually four people from Vivo, and we did it, I think, over like three days in the end.”
quote is from the automated transcript, cleaned for reading: filler sounds and stutters are removed, nothing is rephrased. names can be misheard (the analysis reads context, assessments check outside sources). how →
More from Johnny Yu
Yu: Virtual cell models will directly design disease-reversing drugs
“A big part of our future vision and roadmap is that we think there will be a moment where from a virtual cell model, a drug is spit out, and basically the drug will actually cause a healthy disease cell to become a healthy cell again.”
Yu: Tahoe dataset doubles a decade of cumulative single-cell data
“And so this data set, it is basically doubling the size of all the data that's out there cumulatively over the past decade. It covers 50 different cancer models from different patients, so it's cells from 50 different patients. 1200 drug treatments, so it's a …”
Yu: Cancer perturbation pathways apply broadly to neuroscience and immunology
“This data set, even though it's heavily based around these kinds of chemical perturbations of cancer, they also, these pathways are so conserved and fundamental that they broadly apply to the neuroscience space or like to just immune cell development in genera…”
Johnny Yu: Tahoe-100 is the world's largest single-cell RNA sequencing dataset
“So Tahoe 100 is the world's biggest single cell RNA sequencing data set, and it enables basically a ton of machine learning applications, including things like the virtual cell, but it also enables a lot of drug discovery applications, and broadly in the conte…”